

Box 1 Recommendations

To Member States

1. GGM Phase I countries should address their identified gaps in their action plans.
2. More attention should be given to the structure, mandate and composition of a committee/board of directors/board of trustees. These committees should have in place adequate terms of reference, solid selection criteria for committee members, and standard operating procedures.
3. Countries should make extra efforts to submit their Phase I assessment reports as soon as possible in order to progress to Phase II activities.

To WHO

1. The progress made in each country should be monitored, including the development and implementation of action plans.
2. More focus should be given to disclosure policies that define the type of information that needs to be communicated to each party and in what form, as this would help minimize the abuse of confidentiality.
3. Guidance should be provided to the re-assessment exercise planned by Morocco to document the impact of constitutional and regulatory reforms on GGM as a basis for development of their GGM framework.
4. A case study should be prepared on how the Jordan FDA was established as an autonomous entity governed by a board of directors and regulatory framework, including the challenges faced and solutions found in becoming a well-functioning national regulatory authority.
5. French translation of GGM training materials should be made available for national meetings and workshops.
6. The regional GGM platform for information sharing and technical guidance should be revived.